Drug Discovery World

JUNE 6, 2024

Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. Ultimately it will contribute to survival rates improving continually over the next decades and more.” .

Vaccine 147

Vaccine Clinical Trials FDA Approval Research Laboratories 147

Drug Discovery World

FEBRUARY 14, 2024

Vaccination responses need to be rapid, efficacious and cost-effective if they are to outpace new viral threats emerging across the globe, says Jian He (Jason) , Chemistry, Manufacturing and Controls (CMC) Head, WuXi Vaccines. This would give more people much faster access to more effective vaccines.

Vaccine 147

Vaccine Production Virus DNA 147

Drug Discovery World

MAY 15, 2024

Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. By training the immune system to attack these regions, it gives protection against other coronaviruses not represented in the vaccine.

Vaccine 130

Vaccine Immune Response Clinical Trials Virus 130

Drug Discovery World

MAY 1, 2024

Our preclinical results suggest that our vaccines may significantly outperform them, to transform care for future cancer patients.” It will also support development of Infinitopes’ lead asset, a novel cancer vaccine called ITOP1, which is scheduled to commence a Phase I/IIa study in first line cancer patients in the third quarter of 2024.

Vaccine 147

Vaccine Clinical Trials Research Science 147

Drug Discovery World

OCTOBER 13, 2023

The scientists say the tool can help inform the development of vaccines and therapies for SARS-CoV-2 and other rapidly mutating viruses. The University has also launched a new global consortium to research and develop next-generation Covid-19 and flu vaccines, backed by £8 ($9.8) million funding from UK Research and Innovation (UKRI).

Vaccine 264

Vaccine Virus Medical Schools Immune Response 264

Drug Discovery World

MAY 2, 2024

A study led by the University of Oxford has successfully investigated human immunity against Covid-19 in people who already have antibodies, with the aim of advancing future vaccines and treatments. The results suggest that previous infection, together with vaccination, offers strong protection against the original Covid-19 strain.

Vaccine 147

Vaccine Immune Response Virus Treatment 147

Drug Discovery World

APRIL 18, 2024

For the first time, a controlled human infection model for tuberculosis (TB) has been developed and could help with the future development of TB vaccines. The team states that it’s the first step towards establishing a challenge model that can be used to test new vaccines for TB.

Vaccine 130

Vaccine Clinical Trials Trials Disease 130

Drug Discovery World

JANUARY 16, 2024

Dr Masaru Kanekiyo On Tuesday 6 February at 11.30am, the speaker will be Masaru Kanekiyo, DVM, PhD, Investigator and Chief of Molecular Immunoengineering Section of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), NIH. See the full programme and register your interest in this event.

Vaccine 162

Vaccine Disease Research Drugs 162

Drug Discovery World

APRIL 13, 2023

The R21/Matrix-M malaria vaccine has received regulatory clearance for use in Ghana by the country’s Food and Drugs Authority, making it the first country to approve the vaccine. The vaccine has been approved for use in children aged five to 36 months, the age group at highest risk of death from malaria.

Vaccine 246

Vaccine Clinical Trials Trials Production 246

Drug Discovery World

APRIL 15, 2024

Naobios has signed a partnership agreement with Sumagen, a Korean-Canadian biotechnology company developing an HIV-1 vaccine candidate, to manage the manufacturing process during its Phase II clinical trials. At the end of 2022, the World Health Organization (WHO) reported that approximately 39 million people were living with HIV.

Vaccine 130

Vaccine Clinical Trials Trials Virus 130

Drug Discovery World

APRIL 26, 2024

A clinical trial of a personalised mRNA cancer vaccine for melanoma patients has been launched in the UK. In addition to encoding the target antigens, mRNA vaccines also provide adjuvant properties that amplify the immune response. in the combination arm and 62.2%

Clinical Trials 130

Clinical Trials Vaccine Trials Immune Response 130

Drug Discovery World

JANUARY 8, 2024

UK-based Barinthus Biotherapeutics, the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford are working together to fast-track the development of a vaccine candidate for the prevention of Middle East Respiratory Syndrome (MERS).

Vaccine 147

Vaccine Clinical Trials Licensing Licensing 147

Drug Discovery World

JANUARY 16, 2024

A new study will compare whether giving tuberculosis vaccine by inhalation is better at protecting against tuberculosis (TB) than injection into the skin. The Jenner Institute at the University of Oxford is conducting the study using Bacille Calmette-Guérin (BCG), the current licensed vaccine against TB.

Clinical Trials 147

Clinical Trials Vaccine Trials Immune Response 147

Drug Discovery World

MARCH 13, 2024

UK researchers have highlighted the importance of continued surveillance of emerging SARS-CoV-2 variants and vaccine performance as the virus continues to evolve. The researchers found that both vaccines generated neutralising antibodies against the most recent strain of Omicron, BA.2.86. strains after their booster vaccination.

Vaccine 130

Vaccine Research Virus Hospitals 130

Drug Discovery World

OCTOBER 2, 2023

This eBook sponsored by DNA Script explores the advances and breakthroughs taking place within vaccines and virology.

Vaccine 130

Vaccine RNA DNA Research 130

Drug Discovery World

MARCH 27, 2024

The vaccines currently in late-stage development hold promise in tackling the disease burden of tuberculosis (TB), says data and analytics company GlobalData on World Tuberculosis Day 2024. According to GlobalData, there are 11 vaccines in late-stage development for TB globally. TB remains a global pandemic, with 1.8

Vaccine 130

Vaccine Clinical Trials Licensing Licensing 130

Drug Discovery World

JANUARY 12, 2024

A study has revealed that Covid-19 vaccines are effective in preventing long Covid, but the BioNTech/Pfizer vaccine provided better protection than ChAdOx1, developed by Oxford University/AstraZeneca. We encourage continued efforts to understand and approach treatments for long Covid.”

Vaccine 147

Vaccine Virus Treatment Research 147

PPD

JUNE 24, 2024

In the realm of vaccine development, mega trials — studies enrolling 5,000 subjects or more — have been instrumental in the fight against many pathogens, including influenza, rotavirus, malaria, RSV and most recently in the rapid development of vaccines against COVID-19.

Vaccine 97

Vaccine Trials Clinical Trials Laboratories 97

Drug Discovery World

NOVEMBER 13, 2023

The US Food and Drug Administration (FDA) has approved Ixchiq, Valneva’s single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus (CHIKV). The vaccine is indicated in individuals 18 years of age and older who are at increased risk of exposure to CHIKV. seroresponse rate six months post-vaccination.

FDA Approval 147

FDA Approval Vaccine FDA Virus 147

Drug Discovery World

FEBRUARY 19, 2024

Replicate Bioscience has shared positive results from the Phase I trial of RBI-4000, its srRNA-based rabies vaccine. In this clinical trial, evaluating safety and immunogenicity of RBI-4000 , participants received one or two doses of srRNA vaccine at low doses (0.1mcg, 1mcg or 10mcg).

Vaccine 130

Vaccine Immune Response RNA Virus 130

Drugs.com

JULY 2, 2024

health officials announced Tuesday that the federal government will pay Moderna $176 million to speed development of a pandemic flu vaccine based on mRNA technology.Such a vaccine could be used to treat bird flu in. TUESDAY, July 2, 2024 -- U.S.

Government 111

Government Vaccine 111

Drug Discovery World

FEBRUARY 20, 2024

A five-year contract totalling up to $31 million including programme options has been awarded to Ginkgo Bioworks to discover and develop next-generation vaccine adjuvants. The post Ginkgo Bioworks to discover and develop novel vaccine adjuvants appeared first on Drug Discovery World (DDW).

Vaccine 130

Vaccine Immune Response Licensing Licensing 130

Drug Discovery World

DECEMBER 18, 2023

An effective HIV vaccine may need to prompt strong responses from CD8+ T cells to protect people from acquiring HIV, according to a study from the National Institute of Allergy and Infectious Diseases (NIAID). Further tests revealed that this dampened response was due to reduced sensitivity to HIV of vaccine recipients’ T-cell receptors.

Vaccine 147

Vaccine Clinical Trials Laboratories Virus 147

Drug Discovery World

OCTOBER 11, 2023

MinervaX, a Danish biotechnology company developing a novel, prophylactic vaccine against Group B streptococcus (GBS), has announced the completion of €54 million upsized financing. GBS is a leading cause of life-threatening infections in newborns as well as adverse pregnancy outcomes such as preterm delivery and stillbirths.

Vaccine 147

Vaccine Clinical Trials Trials Science 147

Drug Discovery World

MARCH 15, 2024

Valneva Scotland is focused on vaccines for infectious diseases with significant unmet medical needs. The company’s vaccine for Chikungunya virus (IXCHIQ) was approved by the US Food and Drug Administration (FDA) in November 2023 and is the world’s first and only vaccine for Chikungunya.

Vaccine 147

Vaccine Science Clinical Trials Virus 147

Drug Discovery World

FEBRUARY 28, 2024

The first 20 participants have been enrolled in a multicentre trial to test whether ImmunityBio’s Nant Cancer Vaccine (NCV) could potentially prevent colon and other cancers in individuals with Lynch syndrome. The vaccine comprises a tri-valent Adenovirus (Tri-Ad5) in combination with the company’s IL-15 superagonist N-803.

Vaccine 130

Vaccine Trials Drugs Disease 130

Drug Discovery World

NOVEMBER 28, 2023

In the eighth eBook of the Hamilton series, ‘Assessing the Efficacy of Vaccines through Laboratory Assays’, we discuss: Vaccine development: Key milestones and impact of Covid-19 Laboratory tests commonly used to assess vaccines’ efficacy and the benefits of automating them Hamilton standardised and customised solutions for workflows (..)

Laboratories 130

Laboratories Vaccine Virus Drugs 130

Drug Discovery World

OCTOBER 14, 2022

Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. The post Merck and Moderna to develop a personalised cancer vaccine appeared first on Drug Discovery World (DDW).

Vaccine 244

Vaccine Research Laboratories Laboratories Clinical Development 244

Drug Discovery World

NOVEMBER 2, 2023

The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend Pfizer’s Penbraya (meningococcal group A, B, C, W and Y vaccine) for the prevention of the five most common meningococcal serogroups.

Vaccine 130

Vaccine FDA Approval FDA Disease 130

Drug Discovery World

OCTOBER 3, 2023

The R21/Matrix-M malaria vaccine has been recommended for use by the World Health Organization’s Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG). The developers expect additional regulatory approvals will follow shortly and R21/Matrix-M vaccine doses could be ready to begin wider roll-out next year.

Vaccine 147

Vaccine Clinical Trials Licensing Licensing 147

Drug Discovery World

NOVEMBER 10, 2023

Researchers from Korea conducted a clinical trial to assess the immunogenicity and safety of GBP510/AS03 relative to the ChAdOx1-S vaccine. The participants were split in two groups: those with no prior SARS-CoV-2 infection or Covid-19 vaccination history and those irrespective of these parameters.

Immune Response 130

Immune Response Vaccine Clinical Trials Trials 130

Drug Discovery World

NOVEMBER 28, 2023

In ‘ Assessing the Efficacy of Vaccines through Laboratory Assays ‘, the authors discuss the key milestones achieved throughout the history of vaccine development, the laboratory tests commonly used to assess vaccines’ efficacy, and we describe how the latter can be automated using Hamilton solutions.

Laboratories 130

Laboratories Vaccine Virus Drugs 130

Drug Discovery World

JANUARY 12, 2024

The first clinical trial participants have received doses of the ChAdOx1 NipahB vaccine at the University of Oxford. Despite the first outbreaks occurring 25 years ago in Malaysia and Singapore, there are currently no approved vaccines or treatments. Knowledge gained could also inform development of other Paramyxovirus countermeasures.”

Virus 130

Virus Vaccine Trials Clinical Trials 130

Drug Discovery World

DECEMBER 11, 2023

million grant from the Bill & Melinda Gates Foundation in support of vaccine development. Naobios will manufacture a human viral challenge agent that will be used to evaluate the effectiveness of vaccines in preventing infections and to accelerate the vaccine development process.

Vaccine 130

Vaccine Virus Production Drugs 130

Drug Discovery World

SEPTEMBER 25, 2023

Enrolment in a Phase I trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, US. An ideal universal influenza vaccine could be taken less frequently than once a year and protect against multiple strains of influenza virus.

Vaccine 130

Vaccine Trials Animal Testing Virus 130

Drug Discovery World

JANUARY 18, 2024

With funding from MRC/UKRI, the University of Oxford has assembled a team of scientists, radiologists and clinicians to research and understand the cause and effect of varying responses to vaccination. The results will assist researchers in designing vaccines which will offer greater protection to the most vulnerable.

Vaccine 130

Vaccine Clinical Research Hospitals Trials 130

Drug Discovery World

AUGUST 3, 2023

It becomes the ninth Covid-19 vaccine to be authorised by the UK’s independent medicines regulator. The clinical evidence for the authorisation is based on data from a study of 765 adults who had received primary vaccination with two doses of the Comirnaty Covid-19 vaccine and who were given a booster dose of either Bimervax or Comirnaty.

Vaccine 130

Vaccine Immune Response Clinical Trials Virus 130